% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

  • lws2000 lws2000 Jan 23, 2012 8:12 PM Flag

    BOTOX demand drives AGN to new highs

    Allergan(AGN_) is a multi-specialty healthcare company. It has been given a buy rating by UBS Investment Research due to an improvement in its growth valuations. Earnings per share are expected to grow by more than 15% to 20%.
    The company's Botox line is highly sustainable and Allergan's pipeline is underappreciated at the moment. According to UBS, Allergan's growth profile would be a nice fit with other big pharmaceutical companies. UBS is expecting revenues of $1.4 billion by the end of 2012 and earnings per share of $1. The continued roll-out of Botox Migraine and Botox OAB NDO will be closely watched by UBS.
    Shares of the company are currently trading at $88 per share and are expected to reach a price target of $100, indicating a potential upside of 13.6%. Ken Fisher 's Fisher Asset Management had more than $350 million invested in Allergan at the end of September